Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013
详细信息 查看全文
- 作者：Elaine R. Millera ; EMiller@cdc.gov" class="auth_mail" title="E-mail the corresponding author ; Pedro L. Moroa ; Maria Canoa ; Paige Lewisa ; Marthe Bryant-Genevierb ; Tom T. Shimabukuroa
- 关键词：23-Valent pneumococcal polysaccharide vaccine ; Vaccines ; Immunizations ; Vaccine safety ; Surveillance ; Vaccine Adverse Event Reporting System (VAERS)
- 刊名：Vaccine
- 出版年：2016
- 出版时间：27 May 2016
- 年：2016
- 卷：34
- 期：25
- 页码：2841-2846
- 全文大小：437 K
文摘
- •
No new or unexpected safety concerns were identified after Pneumovax®23 vaccine.
- •
Fever and injection site reactions were the most commonly reported adverse events.
- •
Cellulitis was one of the most commonly reported serious adverse events.